Original InvestigationLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Under a Creative Commons license
open access
Central Illustration
Key Words
acute coronary syndrome
lipoprotein(a)
low-density lipoprotein cholesterol
PCSK9 inhibitor
Abbreviations and Acronyms
ACS
acute coronary syndrome
CI
confidence interval
HDL-C
high-density lipoprotein cholesterol
HR
hazard ratio
IQR
interquartile range
LDL-C
low-density lipoprotein cholesterol
MACE
major adverse cardiovascular events
PCSK9
proprotein subtilisin/kexin type 9
Cited by (0)
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
© 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.